Charles M. Rudin, MD

home / authors / charles-m-rudin-md

Articles

Panelists behind a panel desk, smiling at camera.

Clinical Practice Pearls and the Future of SCLC

Charu Aggarwal, MD, MPH;Taofeek K. Owonikoko, MD, PhD;Charles M. Rudin, MD;Vivek Subbiah, MD;Jared Weiss, MD

August 11th 2022

The panel shares clinical pearls for community oncologists treating small cell lung cancer.

Drs Jared Weiss and Charles Rudin sitting behind a panel desk, smiling at camera.

Investigational Agents in SCLC in the Second Line Setting and Beyond

Charu Aggarwal, MD, MPH;Taofeek K. Owonikoko, MD, PhD;Charles M. Rudin, MD;Vivek Subbiah, MD;Jared Weiss, MD

August 11th 2022

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

Charu Aggarwal, MD, MPH;Taofeek K. Owonikoko, MD, PhD;Charles M. Rudin, MD;Vivek Subbiah, MD;Jared Weiss, MD

August 11th 2022

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

Charu Aggarwal, MD, MPH;Taofeek K. Owonikoko, MD, PhD;Charles M. Rudin, MD;Vivek Subbiah, MD;Jared Weiss, MD

August 2nd 2022

Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.

Drs Taofeek Owonikoko and Vivek Subbiah sitting behind a panel desk, smiling at camera.

Lurbinectedin for SCLC Treatment in the Second-Line Setting

Charu Aggarwal, MD, MPH;Taofeek K. Owonikoko, MD, PhD;Charles M. Rudin, MD;Vivek Subbiah, MD;Jared Weiss, MD

August 2nd 2022

Dr Vivek Subbiah explains the clinical trial data that led to the approval of lurbinectedin for SCLC treatment.

Management of Adverse Events Associated with Durvalumab + Chemotherapy

Charu Aggarwal, MD, MPH;Taofeek K. Owonikoko, MD, PhD;Charles M. Rudin, MD;Vivek Subbiah, MD;Jared Weiss, MD

July 11th 2022

Vivek Subbiah, MD, analyzes adverse events observed with durvalumab plus chemotherapy in patients with SCLC and how they can be managed.

Dr. Rudin on Rova-T in Patients With Small Cell Lung Cancer

Charles M. Rudin, MD

August 18th 2016

Charles M. Rudin, MD, medical oncologist, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T) in patients with recurrent or refractory small cell lung cancer (SCLC).